PARG Inhibitor ETX-19477

Preferred Label : PARG Inhibitor ETX-19477;

NCIt definition : An orally bioavailable, small molecule inhibitor of poly (ADP-Ribose) (PAR) glycohydrolase (PARG), with potential antineoplastic activity. Upon oral administration, PARG inhibitor ETX-19477 targets, reversibly binds to and inhibits the activity of PARG, thereby inhibiting the hydrolysis of PAR chains by PARG. This attenuates DNA repair and induces mitotic arrest, ultimately leading to apoptosis of cancer cells. PARG, the only enzyme responsible for hydrolyzing PAR chains produced by poly (ADP-ribose) polymerase (PARP) 1, plays a key role in the resolution of PARP 1/2-dependent DNA damage repair.;

Molecule name : ETX 19477; ETX-19477;

NCI Metathesaurus CUI : CL1928215;

Details

Origin ID

C205921;

concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Poly(ADP-Ribose) Glycohydrolase [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients